Skip to main content

Dupilumab Safety and Efficacy up to 3 Years in Children Aged 6 Months to 11 Years with Atopic Dermatitis: Results from a Phase III Open-Label Extension Study

In brief

About 9 in 10 children on dupilumab had major eczema improvement at 3 years

In an open-label extension study, 89% to 90% of children aged 6 months to 11 years had at least 75% improvement in eczema severity after up to 152 weeks of dupilumab; about 6 in 10 had at least 90% improvement. Drug-related conjunctivitis was reported in about 3%, but only 56% to 65% completed the study, and there was no control group.

Journal
American journal of clinical dermatology (Q1)
Published
13 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Amy S Paller, Elaine C Siegfried, Michael J Cork, Peter D Arkwright, Lawrence F Eichenfield, Yonghao Ma, et al.
PMID
43024188
DOI
10.1007/s40257-026-01082-7

Why clinicians should know about it

  • Picked for Immunology and Allergy (paper of the day, 14 November 2026): Long-term pediatric atopic dermatitis efficacy and biologic safety

Abstract

BACKGROUND: Dupilumab previously demonstrated safety and efficacy in randomized controlled trials (RCTs) and long-term open-label extension (OLE) studies for up to 2 years in patients with atopic dermatitis (AD) aged ≥ 6 months. OBJECTIVE: We report safety and efficacy up to 3 years from an ongoing OLE study (LIBERTY PED OLE) in young pediatric patients with moderate-to-severe AD. METHODS: Children aged ≥ 6 months to 11 years with moderate-to-severe AD from prior dupilumab RCTs received open-label dupilumab every 4 weeks (200 mg: 5 to < 15 kg; 300 mg: 15 to < 30 kg) or every 2 weeks (200 mg: 30 to < 60 kg; 300 mg: ≥ 60 kg). Concomitant topical medications were permitted. Safety, efficacy, and quality of life (QoL) were assessed at parent study baseline or OLE study baseline through 152 weeks. RESULTS: One hundred and eighty patients 6 months to 5 years old and 383 patients 6 to 11 years old were enrolled; 56.1% and 65.3% completed week 152, respectively. The most frequent drug-related treatment-emergent adverse events (TEAEs) included conjunctivitis (2.8% in the 6 months to 5 years group; 2.6% in the 6 to 11 years group), allergic conjunctivitis (2.8%; 2.6%), and nasopharyngitis (1.7%; 2.1%). Dupilumab resulted in persistent efficacy improvements from parent study baseline and OLE study baseline to week 152. ≥ 75%/90% improvement in Eczema Area and Severity Index scores (EASI-75/EASI-90) at week 152 was achieved in 90.3%/60.2% of patients (6 months to 5 years) and 89.1%/61.1% (6 to 11 years). Similar outcomes were observed in other clinical efficacy (SCORing AD score [SCORAD]-50 and body surface area) and QoL (Infants'/Children's Dermatitis QoL Index) metrics. CONCLUSIONS: In this OLE study, long-term treatment with dupilumab for up to 3 years showed an acceptable safety profile and continued efficacy in infants and children with moderate-to-severe AD, supporting its use in pediatric patients [Graphical Abstracct available online]. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02612454.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.